BofA Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral
More News related to AUXL
- Unusual 11 Mid-Day Movers 12/18: ARYX, GIII, MU, XL Higher; CPY, ADLR, TTWO, SIMG Lower
- BenchmarkJournal.com (Complimentary) Analyst Review for and EXPE, GOLD, AUXL and ASTM
- Morning Movers 12/18: DVAX, ARYX, NOBH, AUXL Higher; CPY, TTWO, TNC, CVD Lower
- Auxilium (AUXL) and Pfizer (PFE) Enter Agreement to Commercialize XIAFLEX(TM) in Europe
- Auxilium (AUXL) In Development Agreement With Pfizer (PFE)
More News related to Downgrades
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Bank of America downgrades Auxilium Pharmaceuticals (Nasdaq: AUXL) from Buy to Neutral.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States.
Related Categories
DowngradesStocks Mentioned
-0.74Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
